Issues lobbied + lobbyists
MMM — Medicare/Medicaid
Medicaid State Directed Payments; 340B modernization; funding for Disproportionate Share Hospitals (Medicaid DSH); funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies; impact of regional oversaturation of trauma care on patient outcomes and health system costs; H.R. 4313/S. 2237, Hospital Inpatient Services Modernization Act; H.R. 267, the Health Care Price Transparency Act; H.R. 2590/S. 1264, the Mental and Physical Health Care Comorbidities Act of 2025.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B modernization; impact of regional oversaturation of trauma care on patient outcomes and health system costs; Pandemic and All Hazards Preparedness Act reauthorization; H.R. 267, the Health care PRICE Transparency Act; H.R. 5256, the 340B ACCESS Act; H.R. 4392, Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
BUD — Budget/Appropriations
Funding for drug therapeutic infusion pumps; H.R. 5371, the Continuing Appropriations and Extensions Act, 2026.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
H.R. 5256, the 340B ACCESS Act.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
DEF — Defense
FY 2027 National Defense Authorization Act.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE